Interferon- and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS
| Autor: | Ingrid van der Mei, Darryl W. Eyles, Niall Stewart, Fotini Pittas, T Dwyer, Bruce V. Taylor, Steve Simpson, Pauline Ko, Anne-Louise Ponsonby, Leigh Blizzard |
|---|---|
| Rok vydání: | 2012 |
| Předmět: | |
| Zdroj: | Neurology. 79:254-260 |
| ISSN: | 1526-632X 0028-3878 |
| DOI: | 10.1212/wnl.0b013e31825fded9 |
| Popis: | Objective: To determine whether interferon-β (IFN-β) medication use is associated with vitamin D levels and whether the two interact in exerting effects on relapse risk. Methods: In a prospective cohort of 178 persons with clinically definite multiple sclerosis (MS) living in southern Tasmania in 2002–2005, serum 25-hydroxyvitamin D [25(OH)D] was measured biannually, with assessment by questionnaire for relevant factors, including IFN-β treatment. Results: Subjects reporting IFN-β use had significantly higher mean 25(OH)D than persons who did not ( p p = 0.82). 25(OH)D was associated with a reduced relapse risk only among persons on IFN-β ( p Conclusion: In this study, we found that IFN-β therapy is associated with greater production of vitamin D from sun exposure, suggesting part of the therapeutic effects of IFN-β on relapse in MS may be through modulation of vitamin D metabolism. These findings suggest persons being treated with IFN-β should have vitamin D status monitored and maintained in the sufficiency range. Classification of evidence: This study provided Class III evidence that IFN-β is associated with reduced risk of relapse, and this effect may be modified by a positive effect of IFN-β on serum 25(OH)D levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|